Michael Cloutier is the President and CEO of AstraZeneca Canada Inc., one of Canada's
leading pharmaceutical companies.
With over 23 years of pharmaceutical industry experience, Mr. Cloutier was appointed
president and CEO of AstraZeneca Canada Inc. on October 1st, 2003. He recently served as
president and CEO of the former Pharmacia Canada organization. Prior to the merger of Pharmacia
& UpJohn with the Monsanto Company and its G.D. Searle unit, he was President of Searle
Canada. He has also worked with the industry in Latin America.
He currently serves on the Executive Committee of the Board of Directors for Canada's Research
Based Pharmaceutical Companies (Rx&D) as Treasurer and is also Chair of the Ontario
Regional Committee. Mike also serves on a number of boards including the Canadian Stroke
Network, the Canadian Pharmaceutical Distribution Network (CPDN), the ACT Foundation, the
Toronto Downtown Jazz Festival and the Board of Governors of Joseph Brant Memorial Hospital.
Mike is the chair of the University of Toronto at Mississauga Hazel McCallion Academic Learning
Centre project and sits on the Humber College Curriculum Advisory Board. In November 2005, he
was inducted into the Canadian Healthcare Marketing Hall of Fame.
AstraZeneca is one of the leading global pharmaceutical companies with a formidable product
portfolio spanning six major therapeutic areas: gastrointestinal, cardiovascular, oncology,
respiratory, neuroscience and infection.
Ranked as one of the top 50 employers in Canada by The Globe and Mail's Report on Business
Magazine for the fourth consecutive year, AstraZeneca's Canadian headquarters and manufacturing
facilities are located in Mississauga, Ontario, with a state-of-the-art basic pain research
centre based in Montreal, Quebec.